Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint

The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenyon, Chris, Laumen, Jolein, Manoharan-Basil, Sheeba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147325/
https://www.ncbi.nlm.nih.gov/pubmed/34062856
http://dx.doi.org/10.3390/antibiotics10050515
_version_ 1783697604412964864
author Kenyon, Chris
Laumen, Jolein
Manoharan-Basil, Sheeba
author_facet Kenyon, Chris
Laumen, Jolein
Manoharan-Basil, Sheeba
author_sort Kenyon, Chris
collection PubMed
description The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gonorrhoeae via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal Neisseria. We illustrate the benefits of this pan-Neisseria strategy by evaluating three contemporary treatment options for N. gonorrhoeae—ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin.
format Online
Article
Text
id pubmed-8147325
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81473252021-05-26 Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint Kenyon, Chris Laumen, Jolein Manoharan-Basil, Sheeba Antibiotics (Basel) Viewpoint The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gonorrhoeae via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal Neisseria. We illustrate the benefits of this pan-Neisseria strategy by evaluating three contemporary treatment options for N. gonorrhoeae—ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin. MDPI 2021-05-01 /pmc/articles/PMC8147325/ /pubmed/34062856 http://dx.doi.org/10.3390/antibiotics10050515 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Viewpoint
Kenyon, Chris
Laumen, Jolein
Manoharan-Basil, Sheeba
Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint
title Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint
title_full Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint
title_fullStr Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint
title_full_unstemmed Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint
title_short Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint
title_sort choosing new therapies for gonorrhoea: we need to consider the impact on the pan-neisseria genome. a viewpoint
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147325/
https://www.ncbi.nlm.nih.gov/pubmed/34062856
http://dx.doi.org/10.3390/antibiotics10050515
work_keys_str_mv AT kenyonchris choosingnewtherapiesforgonorrhoeaweneedtoconsidertheimpactonthepanneisseriagenomeaviewpoint
AT laumenjolein choosingnewtherapiesforgonorrhoeaweneedtoconsidertheimpactonthepanneisseriagenomeaviewpoint
AT manoharanbasilsheeba choosingnewtherapiesforgonorrhoeaweneedtoconsidertheimpactonthepanneisseriagenomeaviewpoint

Ejemplares similares